Regeneron Pharmaceuticals, Inc. announced on September 17 that it had completed a phase 3 trial for a drug to treat fibrodysplasia ossificans progressiva (FOP). FOP is a severe, ultra-rare genetic disorder that forms bone in connective tissues, which may significantly restrict mobility and result in an early death. Regeneron’s trial medicine reduced new bone lesions in FOP patients by over 90 percent. After announcing the positive news, Aris Economides, vice president of research at Regeneron, shared his excitement with UC Berkeley’s dean of biological sciences, Richard Harland. It was Harland’s mid-1990s discovery of a gene and its associated protein that prompted Regeneron down a winding path that eventually led to its potential FOP treatment — a demonstration of basic research’s value to society.
Dr. Johan Klingborg is a Professor in the Department of Scandinavian. He works on nineteenth-, twentieth-, and twenty-first-century Scandinavian literature, and his research largely focuses on its intersections with media networks. Dr. Klingborg received his PhD in Literary Studies from Stockholm University in 2024. 
Alexandra Lossada works on immigration, citizenship, and language in contemporary American ethnic literatures, especially in Latinx and Chicanx writing. Her current manuscript project, tentatively entitled The Interpreter of Crimmigration and Detention, reevaluates the figure and the role of the interpreter in post-9/11 literary works that depict detention, deportation, and/or...
